Predicting the status of the nonsentinel axillary nodes: a multicenter study.

BACKGROUND Sentinel lymph node (SLN) biopsy is a minimally invasive procedure that provides accurate nodal staging information. The need for completion axillary dissection after finding a positive SLN for breast cancer has been questioned. HYPOTHESIS The presence of nonsentinel node (NSN) metastases in the axillary dissection specimen correlates with tumor size, the number of SLNs removed, and the number of positive SLNs. DESIGN Prospective, multi-institutional study. PARTICIPANTS AND METHODS The University of Louisville Breast Cancer Sentinel Lymph Node Study is a nationwide study involving 148 surgeons. All patients underwent SLN biopsy, followed by level I/II axillary dissection. All SLNs were evaluated histologically at a minimum of 2-mm intervals. Immunohistochemical analysis using antibodies for cytokeratin was performed at the discretion of each participating institution. All NSNs were evaluated by routine histologic examination. RESULTS An SLN was identified in 1268 (90%) of 1415 patients. Increasing tumor size was significantly correlated with increasing likelihood of positive NSNs: T1a, 14%; T1b, 22%; T1c, 30%; T2, 45%; and T3, 57% (P =.002, chi(2) test). The presence of positive NSNs was not significantly associated with the number of SLNs removed. Patients with more than 1 positive SLN were more likely to have positive NSNs than those with only 1 positive SLN (50% vs 32%; P<.001, chi(2) test). Increasing tumor size and the presence of multiple positive SLNs were also associated with the presence 4 or more positive axillary nodes. Multivariate analysis confirmed that tumor size and the number of positive SLNs were independent factors predicting the presence of positive NSNs. CONCLUSIONS The likelihood of positive NSNs correlates with increasing tumor size and the presence of multiple positive SLNs. However, even patients with small primary tumors have a substantial risk of residual axillary nodal disease after SLN biopsy. These data will be helpful in counseling patients regarding the need for completion axillary dissection after a positive SLN is identified.

[1]  A. Giuliano,et al.  Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node , 2000, Cancer.

[2]  K. McMasters,et al.  Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. , 2000, Surgery.

[3]  P B Cerrito,et al.  Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Reintgen,et al.  The role of sentinel lymph node biopsy in breast cancer. , 1999, Journal of the American College of Surgeons.

[5]  J. Donohue,et al.  Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Cody,et al.  Sentinel lymphatic mapping in breast cancer. , 1999, Journal of the American College of Surgeons.

[7]  A E Giuliano,et al.  Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? , 1999, Annals of surgery.

[8]  E. Conant,et al.  Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma , 1999, Cancer.

[9]  A. Luini,et al.  Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. , 1999, Journal of the National Cancer Institute.

[10]  R. Orr.  The Impact of Prophylactic Axillary Node Dissection on Breast Cancer Survival—A Bayesian Meta-Analysis , 1999, Annals of surgical oncology.

[11]  D. Reintgen,et al.  Microstaging of Breast Cancer Patients Using Cytokeratin Staining of the Sentinel Lymph Node , 1999, Annals of Surgical Oncology.

[12]  A. Giuliano,et al.  Sentinel Node Metastasis in Patients with Breast Carcinoma Accurately Predicts Immunohistochemically Detectable Nonsentinel Node Metastasis , 1999, Annals of Surgical Oncology.

[13]  A E Giuliano,et al.  Sentinel-lymph-node biopsy for breast cancer--not yet the standard of care. , 1998, The New England journal of medicine.

[14]  R. Foster,et al.  The sentinel node in breast cancer--a multicenter validation study. , 1998, The New England journal of medicine.

[15]  M. Silverstein,et al.  Predictors of axillary lymph node metastases in patients with T1 breast carcinoma , 1997, Cancer.

[16]  M. Fan,et al.  Lymph node micrometastases from breast carcinoma , 1997, Cancer.

[17]  A. Giuliano,et al.  Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. , 1997, Annals of surgery.

[18]  B. Cady.  Use of primary breast carcinoma characteristics to predict lymph node metastases , 1997, Cancer.

[19]  M. R. Shetty,et al.  Tumor size and axillary metastasis, a correlative occurrence in 1244 cases of breast cancer between 1980 and 1995. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  A. Giuliano,et al.  Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. , 1996, Journal of the American College of Surgeons.

[21]  S Hellman,et al.  Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Asselain,et al.  Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer , 1992, The Lancet.

[23]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[24]  G. Hortobagyi,et al.  The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. , 1989, Archives of surgery.

[25]  M. Caleffi,et al.  The significance of local control in the primary treatment of breast cancer. Lucy Wortham James clinical research award. , 1987, Archives of surgery.

[26]  B. V. Pedersen,et al.  Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer , 1985, The British journal of surgery.

[27]  S. Koscielny,et al.  Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. , 1984, British Journal of Cancer.

[28]  C. Redmond,et al.  The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. , 1981, Surgery, gynecology & obstetrics.

[29]  G. Murphy,et al.  Management and survival of female breast cancer: Results of a national survey by the American college of surgeons , 1980, Cancer.

[30]  A. Nash,et al.  Ten‐year results of the treatment of primary operable breast carcinoma. A summary of 304 patients evaluated by the TNM system , 1976, Cancer.

[31]  J. Hayward,et al.  Treatment of Early Breast Cancer: A Report after Ten Years of a Clinical Trial , 1972, British medical journal.

[32]  I D Bross,et al.  Cancer of the breast: Size of neoplasm and prognosis , 1969, Cancer.